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iabetes is a metabolic disease whose incidence and prevalence has significantly increased in
recent decades, mainly because of an increase in type 2 diabetes, which represents almost
90% of all cases of diabetes. The World Health Organization estimates that, by 2025, there
will be 300 million diabetic patients (5.4% of the world population). Older patients are most
affected by diabetes, as the disease prevalence increases with age, at least up until 75 years. The
progressive aging of the global population could explain about half of the predicted increase of
diabetic patients in the near future.1
Macrovascular disease (coronary artery disease, stroke, and peripheral vascular disease) is
responsible for the majority of morbidity and mortality associated with type 2 diabetes. In the UK
prospective diabetes study (UKPDS),2 the 10 year risk of all macrovascular complications was four
times that of microvascular complications. Coronary artery disease is the leading cause of death
among diabetic patients, and women have a higher cardiovascular risk than men.
Diabetics have aworse prognosis after an acute coronary syndrome than non-diabetic patients. This
was documented both for ST elevation and non-ST elevation acute myocardial infarction (AMI). The
Framingham heart study has also shown a higher mortality rate, as well as reinfarction and heart
failure rates, in diabetic patients, both during the acute phase and in the post-infarction period, even
after data adjustment for other risk factors.1 Diabetic patients may, therefore, derive a greater benefit
from therapies shown to be effective in treating ischaemic heart disease.
The challenge is, therefore, to protect the heart of diabetic patients more effectively. Can we
achieve this goal? To answer this question we must first understand why patients with diabetes
have a higher cardiovascular risk.
MECHANISMS FOR CARDIOVASCULAR DAMAGE AND PROTECTION IN THE
DIABETIC HEARTc
Preconditioning
Preconditioning is the mechanism by which brief periods of sublethal ischaemia can render a
heart more resistant to subsequent periods of more prolonged ischaemia (table 1).
In animal studies, infarct size was linearly related to blood glucose concentration during acute
hyperglycaemia and during diabetes, in the presence or absence of preconditioning stimuli.
Increases in serum osmolality caused by administration of raffinose did not increase infarct size
or interfere with the ability of preconditioning to protect against infarction. These results indicate
that hyperglycaemia is a major determinant of the extent of myocardial infarction.
Other studies showed different findings. Using a rabbit infarct model, it was shown that there
was a significant positive correlation between area at risk and infarct size in both diabetic and
non-diabetic hearts and, for a given area at risk, diabetic rabbits developed smaller myocardial
infarctions than controls. In additional experiments, hyperglycaemia induced by intravenous
glucose infusion in non-diabetic rabbits did not protect the ischaemic myocardium. It was
concluded that diabetes in the rabbit induces a chronic and metabolic form of preconditioning.
Animal studies have shown that ischaemic preconditioning does not protect hearts from obese
or lean type 2 diabetic animals. However, the susceptibility of the type 2 diabetic myocardium to
ischaemic damage is lower than in non-diabetic hearts. In a study performed in dogs, infarct size
was directly related to blood glucose concentrations in diabetic animals, but this relationship was
abolished by higher concentrations of isoflurane. The results indicate that blood glucose and end
tidal isoflurane concentrations are important determinants of infarct size during anaesthetic
induced preconditioning.
The activation of pro-survival kinases, such as Akt and Erk1/2 (which have been termed the
reperfusion injury salvage kinase (RISK) pathway),3 at the time of reperfusion, has been
demonstrated to confer powerful cardioprotection against myocardial ischaemia–reperfusion
injury. Evidence exists suggesting that the cardioprotective phenomena of ischaemic precondi-
tioning and the recently described ischaemic postconditioning exert their cardioprotective effects
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through the recruitment of the RISK pathway,3 at the time of
reperfusion, and that the protection in these settings is
mediated through the inhibition of mitochondrial perme-
ability transition pore opening at this time.4
Studies show that the differential pattern of protein kinase
cascade activation in the diabetic heart might account for the
modulation of their response to ischaemia. It is also known
that the protective effect of ischaemic preconditioning
against myocardial ischaemia may come from improved
energy balance. Under ischaemic conditions, more glycolytic
metabolites are produced in the diabetic rats, and precondi-
tioning inhibited these metabolic changes similarly in both
groups. This suggests that diabetic myocardium may benefit
more from preconditioning than normal myocardium,
possibly as a result of reduced production of glycolytic
metabolites during ischaemia and concomitant attenuation
of intracellular acidosis.
Protein kinase C (PKC) has also been implicated in
ischaemic preconditioning. Several studies have shown that
PKC activation may contribute to the increased resistance of
the diabetic heart to ischaemia–reperfusion injury.
Angiotensin II alters specific modulators of ischaemic
injury, such as PKC and calcium transport. Exposure of
glucose treated cells to angiotensin II during the pre-hypoxic
period blocks glucose mediated cardioprotection. The reversal
of hyperglycaemic preconditioning was associated with
enhanced accumulation of calcium during hypoxia, an effect
prevented by inhibition of the Na+/H+ exchanger and the T
type calcium channel.
Diabetes and the resulting hyperglycaemia may also
interfere with the cardioprotective effect of ischaemic late
preconditioning, a phenomenon similar to preconditioning,
but which is induced by a brief period of myocardial
ischaemia 24 hours before ischaemia–reperfusion.
Hyperglycaemia before and during the ischaemic period
tended to increase infarct size and blocked cardioprotection
by late preconditioning. Short term insulin treatment does
not restore the cardioprotective effects of late precondition-
ing. Therefore, acute hyperglycaemia and diabetes block the
cardioprotection induced by late preconditioning and cardio-
protection is not restored by short term insulin treatment.
In another study performed to determine the effects of
preconditioning on injury and expression of heat shock
protein 70 in diabetic rat hearts, it was shown that, in
addition to a greater susceptibility to ischaemic insults, the
delayed cardioprotection of preconditioning was lost, and
that this could at least partially be due to impaired synthesis
of stress inducible heat shock protein 70 in diabetic rats.
Other mechanisms
Ischaemic heart from the mildly diabetic animal resists the
accumulation of calcium, a major cause of necrosis. However,
the severely diabetic heart is more susceptible to ischaemia
because of enhanced oxidative stress and eicosanoid
mediated injury, accumulation of undesirable metabolic
products, vascular dysfunction, and impairment in glycolytic
ATP generation.
On the other hand, a number of pathogenic mechanisms can
worsen the ischaemic injury by the superimposition of
hypertension on diabetes. First, the coexistence of the two
diseases leads to cardiac hypertrophy, enhancing susceptibility
to ischaemic damage. Second, hypertension is associated with
activation of neurohumoral mechanisms capable of exacerbat-
ing myocardial injury after an ischaemia–reperfusion insult.
Third, the severity of the diabetic cardiomyopathy worsens
when hypertension coexists. Diabetes and glucose intolerance
may interact with certain survival pathways, through the
activation of PKC and the downregulation of the Na+/H+
exchanger. Hypertension may also interact with these path-
ways through b adrenergic induced activation of PKC and salt
induced alterations in the Na+/H+ exchanger. Elevations in
afterload interfere with the ability of glucose intolerant and
hypertensive rats to activate these and other survival pathways,
thus increasing cell death.5
In diabetes mellitus, locally produced angiotensin II may
lead to oxidative damage. Thus, angiotensin II receptor
blockade may work as a cardioprotective mechanism by
blocking the cardiac renin–angiotensin system.6
It has also been shown that the function and density of
ATP sensitive potassium (KATP) channels, essential in
ischaemic preconditioning, is altered in diabetic rat ventri-
cular myocytes. Blockade of these channels by some
sulfonylureas may worsen myocardial ischaemia by prevent-
ing preconditioning and may be responsible for the high
cardiovascular mortality associated with diabetes.
In diabetics, excessive ethanol ingestion can further
increase the cardiovascular risk. Ethanol is metabolised to
acetaldehyde, a two-carbon carbonyl compound that can
react with nucleophiles to form covalent addition products
(Amadori products). These products are the precursors to the
so called advanced glycation end products (AGE), which
accumulate over time on plasma lipoproteins and vascular
wall components and play an important role in the
development of diabetes related cardiovascular disease.
STRATEGIES FOR PROTECTING THE DIABETIC HEART
Lifestyle changes
Cardioprotection by regular exercise may be exerted synergis-
tically through improvement in many risk factors, in addition
to direct effects on the myocardium, resulting in cardioprotec-
tion against ischaemia–reperfusion injury (table 2).
Cardioprotective effects may include the development of
collateral coronary arteries, induction of myocardial heat shock
proteins, and improved cardiac antioxidant capacity.
Diabetic rats fed with a low ethanol diet showed a decrease
in Hb-AGE when compared with diabetic controls.
Circulating concentrations of HbA1c were unaffected by
ethanol, pointing to the specificity of this action. These data
suggest a possible mechanism for the so called ‘‘French
paradox’’, the cardioprotection conferred by moderate etha-
nol ingestion.
Hypoglycaemic drugs
Large clinical trials data
In UKPDS,2 type 2 diabetes patients were randomised to
conventional versus intensive treatment (sulfonylureas or
Table 1 Preconditioning: key points
c Preconditioning is the mechanism by which brief periods of sublethal
ischaemia can render a heart more resistant to subsequent periods of
more prolonged ischaemia
c The RISK pathway is important in preconditioning
c Mitochondria are also involved in ischaemic preconditioning
c Angiotensin II blockade mimics preconditioning
c Diabetes also affects late preconditioning




insulin, aiming at a fasting glycaemia below 108 mg/dl); in a
subgroup of obese patients, metformin was used as the
primary therapeutic agent. This study has shown a significant
decrease of microvascular (but not macrovascular) complica-
tions with an intensive treatment regimen. Subgroup analysis
showed that metformin decreased macrovascular risk in
obese patients.
The DIGAMI (diabetes mellitus, insulin glucose infusion in
acute myocardial infarction) study enrolled patients with
AMI who received insulin and glucose intravenously or
conventional treatment. One year follow up results showed a
30% lower mortality rate in the intensive treatment group.
Subsequent studies suggested that treatment with intra-
venous insulin can have positive effects upon several aspects
of the disease (besides glucose values).7
In DIGAMI 2, three treatment strategies were compared:
acute insulin–glucose infusion followed by insulin based long
term glucose control; insulin–glucose infusion followed by
standard glucose control; and routine metabolic management
according to local practice. The primary end point was all
cause mortality. DIGAMI 2 did not support the finding that
an acutely introduced, long term insulin treatment improves
survival in diabetic patients following myocardial infarction
when compared with a conventional management at similar
levels of glucose control, or that insulin based treatment
lowers the number of non-fatal myocardial reinfarctions and
strokes.8 However, the DIGAMI 2 investigators stress that an
epidemiological analysis confirms that the glucose value is a
strong, independent predictor of long term mortality in these
patients, emphasising that glucose control seems to be
important in their management.
Other data
Using an animal model of reperfusion after low flow
ischaemia, it was shown that insulin perfusion increased
pre-ischaemic myocardial glycogen content in both diabetic
and control hearts. Recovery of cardiac performance and
myocardial creatine phosphate concentrations in the absence
of insulin was greater in the diabetic hearts during reperfu-
sion. Insulin perfusion improved recovery of cardiac perfor-
mance and elevated creatine phosphate concentrations in
both diabetic and control hearts. Results demonstrate greater
cardioprotection against ischaemia/reperfusion injury in
diabetics and with insulin perfusion.
Insulin mediated cardioprotection is independent of the
presence of glucose at reperfusion. Moreover, the cell survival
benefit of insulin is temporally dependent, in that insulin
administration from the onset of reperfusion and maintained
for either 15 minutes or for the duration of reperfusion
reduced infarct size. In contrast, protection was abrogated if
insulin administration was delayed until 15 minutes into
reperfusion.9
In patients with type 2 diabetes, the use of sulfonylurea
drugs may be harmful by preventing endogenous cardiopro-
tective mechanisms; sulfonylurea drugs increased early
mortality in diabetic patients after direct angioplasty for
AMI. However, not all sulfonylureas are equal. Glimepiride is
pharmacologically distinct from glibenclamide because of
differences in receptor binding properties, which could result
in a reduced binding to cardiomyocyte KATP channels.
Results show that either acute loading or long term use of
sulfonylureas may abolish the preconditioning response in
humans. In fact, like ischaemic animals, diabetics seem to be
much more cardiovascularly sensitive to sulfonylureas.
Selective blockade of myocardial KATP channels with
glibenclamide at therapeutic doses is associated with
significantly impaired cardioprotection and, thereby, con-
tributes to this increase in mortality. Unlike glibenclamide,
glimepiride does not block the mitochondrial KATP channels
of the myocardium. This finding is especially important in
older persons with diabetes, in whom preconditioning has
been shown to be impaired by attenuated activation of KATP
channels. Acute or chronic administration of glibenclamide,
but not glimepiride, induces potentially harmful cardiovas-
cular effects in both diabetic and non-diabetic patients with
coronary artery disease.10 In clinical studies, glimepiride was
generally associated with a lower risk of hypoglycaemia and
less weight gain than other sulfonylureas.
Are these data clinically relevant? In a study involving 602
diabetic and non-diabetic patients admitted for AMI, in-
hospital mortality in diabetic patients was higher than in
non-diabetic patients suffering AMI, regardless of whether or
not they had been treated with sulfonylureas.
Therefore, despite clear evidence for an impairment of
ischaemic preconditioning by sulfonylureas from various
animal studies and from indirect experimental studies in
humans, there is still little evidence these agents lower
cardiovascular mortality in patients with type 2 diabetes
mellitus. Glibenclamide—a sulfonylurea with well documen-
ted negative effects on ischaemic preconditioning under
experimental conditions—failed to alter cardiovascular mor-
tality in the UKPDS.2 Taking smaller follow up studies into
consideration, sulfonylureas do not appear to worsen the
prognosis of patients with type 2 diabetes after AMI. In
contrast, sulfonylurea treatment may increase mortality in
patients with type 2 diabetes when subjected to elective or
emergency balloon angioplasty.10
This early risk is not explained by ventricular arrhythmias,
but may reflect deleterious effects of sulfonylurea drugs on
myocardial tolerance for ischaemia/reperfusion. However, for
surviving patients, sulfonylureas were not associated with
increased risk of serious late adverse events.11
To clarify these effects, a double blind placebo controlled
study was performed; the period of total coronary occlusion
during balloon angioplasty of high grade coronary artery
stenoses was used to compare the effects of glibenclamide
and glimepiride. Mean ST segment shifts decreased in the
glimepiride group, unlike the glibenclamide group.
Accordingly, time to angina during balloon occlusion
increased in the glimepiride group and remained unchanged
in the glibenclamide group, showing that glimepiride
maintains preconditioning, while glibenclamide might pre-
vent it.
Another study assessed the effects of treatment with
glibenclamide or insulin on the extension of left ventricular
Table 2 Cardioprotection provided by the different
hypoglycaemic agents: key points
c Exercise is an important part of the treatment
c Tight glucose control is essential
c Metformin decreases macrovascular complications in obese patients
c Sulfonylureas may have different impacts in cardioprotection





dysfunction induced by acute ischaemia. Each patient was
randomly assigned to either insulin or glibenclamide.
Treatment was crossed over after 12 weeks and maintained
for another 12 weeks. Results indicated that ischaemic
myocardial dysfunction induced by dipyridamole infusion is
less severe during treatment with insulin than with
glibenclamide. Restitution of a preconditioning mechanism
in insulin treated patients may be the potential beneficial
mechanism.
Glitazones—peroxisome proliferator activated receptor c
agonists—act as insulin sensitisers. Data mainly from
preclinical studies suggest that glitazones protect the heart
from acute ischaemia/reperfusion injury and also might
attenuate cardiac remodelling and heart failure.
Mechanisms involved in this cardioprotection are multi-
factorial and not yet completely understood. Glitazones
decrease triglycerides, fibrinogen, visceral fat, blood pressure,
and microalbuminuria, and improve vascular function.
However, fluid retention by glitazones may induce or worsen
congestive heart failure in diabetics with left ventricular
dysfunction.
Cardiovascular drugs
b Blockers have an established role in cardioprotection, both
in primary and secondary preventive studies, and there is
evidence that their cardioprotection is even greater in
diabetics.12 Common belief that b blockers increase the
complication rate in diabetes and worsen glycaemic control
has no scientific basis and should not limit their use in
diabetics with coronary artery disease.
As both angiotensin II and renin–angiotensin system
activation are important deleterious factors in diabetes, it is
not surprising that angiotensin converting enzyme (ACE)
inhibitors confer a notable survival benefit in diabetics with
heart failure12 and/or coronary artery disease,13 as emphasised
by current guidelines.14
Candesartan, an angiotensin II receptor blocker, lowers
blood pressure and preserves left ventricular diastolic
function in diabetic rat hearts. It also reduces the thickening
of the capillary basement membrane, decreasing cardiomyo-
cyte diameter, increasing matrix metalloproteinase-2 activity,
and decreasing inflammatory cytokines. These mechanisms
may explain why, in diabetics with heart failure15 and
coronary artery disease,16 angiotensin II receptor blockers
are endorsed by current guidelines.
Diabetic dyslipidaemia is characterised by moderately high
concentrations of serum cholesterol and triglycerides, small
and dense low density lipoprotein (LDL) particles, and low
high density lipoprotein (HDL) cholesterol concentrations.
Recent clinical trials have demonstrated the benefits of
statins in both diabetic and non-diabetic patients, thus
supporting aggressive treatment of diabetic dyslipidaemia for
coronary artery disease prevention. It is believed that an
important part of the derived benefit in diabetics may be due
to the pleiotropic effects of statins (improvement in
endothelial function, and anti-inflammatory and anti-
oxidant effects).
Other strategies
Studies suggest that the attenuation of the protection
afforded by ischaemic preconditioning in diabetic rats may
be related to the decrease in calcitonin gene related peptide
release. Others have demonstrated that the myocardial
protective effect induced by heat stress could not be extended
to the diabetic rat and that it seems to be unrelated to the
heat shock protein 70 concentration.17 These data may be
used in the future to improve cardioprotection in the diabetic
population.
Can we achieve preconditioning in the human diabetic
heart?
In a study to assess the impact of diabetes on ischaemic
preconditioning, patients with a first anterior wall AMI who
underwent emergency catheterisation less than 12 hours
following onset of chest pain were studied: 490 patients
without diabetes and 121 patients with non-insulin treated
diabetes. Prodromal angina limited infarct size, enhanced
recovery of left ventricular (LV) function, and improved
survival in non-diabetics with AMI. Such beneficial effects
were not observed in diabetics, suggesting that diabetes
might prevent preconditioning.18
In an echocardiographic substudy of the HEART (early
afterload reducing therapy) trial, the hypothesis that prior
angina pectoris confers protection from remodelling after
AMI was studied. LV dilation from days 1 to 90 was used as a
measure of LV remodelling. In patients with angina during
the three months preceding AMI, LV volume change and
maximal creatine kinase were significantly lower. These
protective effects may be secondary to recruitment of
collaterals or ischaemic preconditioning of the myocardium
and appear to be attenuated in diabetics.19
A prospective randomised study performed in diabetics
undergoing coronary artery bypass graft surgery showed
preoperative administration of isoflurane had a cardiopro-
tective effect. Such an effect was prevented by glibenclamide,
but could be restored in diabetics by preoperative shift from
glibenclamide to insulin.
Studies performed in human tissue have investigated the
effects of ischaemic preconditioning on diabetic and failing
human myocardium and the role of mitochondrial KATP
channels on the response in these diseased tissues. Ischaemia
caused similar injury in both normal and diseased tissue.
Preconditioning did not prevent the effects of ischaemia in
diabetics. In the diazoxide treated groups, protection was
mimicked in all groups except the diabetics. Interestingly,
glibenclamide abolished protection in non-diabetic and diet
controlled diabetic groups and did not affect diabetics
receiving KATP channel blockers or insulin. These results
show that failure to precondition the diabetic heart is caused
by dysfunction of the mitochondrial KATP channels, and that
the mechanism of failure in the diabetic heart lies in
elements of the signal transduction pathway which are
different from the mitochondrial KATP channels.20
CONCLUSIONS
In recent years, the importance of diabetes as a cardio-
vascular risk factor has increased. The myocardial meta-
bolism of diabetic patients is significantly impaired, due to
several factors that determine a significant decrease in the
mechanisms that protect the heart from insults, such as
preconditioning, in regard to ischaemia/reperfusion injury.
In order to change this reality, recent emphasis has been
placed on optimising diabetes treatment (namely using
insulin and cardioprotective oral hypoglycaemic drugs), as
well as anti-ischaemic therapy. In the near future, knowledge
from basic research—namely, improvement strategies for




significant improvement in cardioprotection, thus decreasing
the morbidity and mortality associated with diabetes.
Additional references appear on the Heart website—http://
www.heartjnl.com/supplemental
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